Drug Trial Radar · NCT00896532
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
419
Actual
Start
Jun 3, 2009
Primary completion
Feb 21, 2011
Study completion Feb 18, 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.
Conditions
- Low Bone Mineral Density
- Postmenopausal Osteoporosis
Interventions
Placebo to RomosozumabDrug
Administered by subcutaneous injection QM or Q3M.
AlendronateDrug
Administered orally once a week
TeriparatideDrug
Teriparatide 20 μg administered by subcutaneous injection once a day
RomosozumabDrug
Administered by subcutaneous injection
DenosumabDrug
Denosumab 60 mg administered by subcutaneous injection Q6M
Placebo to DenosumabDrug
Administered by subcutaneous injection Q6M
Zoledronic acidDrug
Zoledronic acid 5 mg administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline at Month 12 in BMD at the Lumbar SpineTime frame: Baseline to 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.